These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18537664)

  • 41. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
    Blasko I; Grubeck-Loebenstein B
    Drugs Aging; 2003; 20(2):101-13. PubMed ID: 12534311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preplaque ('preclinical') Aβ-induced inflammation and nerve growth factor deregulation in transgenic models of Alzheimer's disease-like amyloid pathology.
    Cuello AC; Ferretti MT; Iulita MF
    Neurodegener Dis; 2012; 10(1-4):104-7. PubMed ID: 22261363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclooxygenase inhibitors: a novel direction for Alzheimer's management.
    Nivsarkar M; Banerjee A; Padh H
    Pharmacol Rep; 2008; 60(5):692-8. PubMed ID: 19066416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes.
    Hüll M; Müksch B; Akundi RS; Waschbisch A; Hoozemans JJ; Veerhuis R; Fiebich BL
    Neurochem Int; 2006 Jun; 48(8):663-72. PubMed ID: 16546299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.
    Gasparini L; Rusconi L; Xu H; del Soldato P; Ongini E
    J Neurochem; 2004 Jan; 88(2):337-48. PubMed ID: 14690522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.
    Tocco G; Freire-Moar J; Schreiber SS; Sakhi SH; Aisen PS; Pasinetti GM
    Exp Neurol; 1997 Apr; 144(2):339-49. PubMed ID: 9168834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.
    Choi SH; Bosetti F
    Aging (Albany NY); 2009 Feb; 1(2):234-44. PubMed ID: 20157512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?
    Trepanier CH; Milgram NW
    J Alzheimers Dis; 2010; 21(4):1089-99. PubMed ID: 21504126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
    Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
    Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease.
    Yermakova AV; O'Banion MK
    Neurobiol Aging; 2001; 22(6):823-36. PubMed ID: 11754989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
    Blume C; Heise G; Mühlfeld A; Bach D; Schrör K; Gerhardz CD; Grabensee B; Heering P
    Kidney Int; 1999 Nov; 56(5):1770-8. PubMed ID: 10571785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
    Weggen S; Eriksen JL; Das P; Sagi SA; Wang R; Pietrzik CU; Findlay KA; Smith TE; Murphy MP; Bulter T; Kang DE; Marquez-Sterling N; Golde TE; Koo EH
    Nature; 2001 Nov; 414(6860):212-6. PubMed ID: 11700559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.
    Lee M; McGeer E; McGeer PL
    Neurobiol Aging; 2015 Jan; 36(1):42-52. PubMed ID: 25169677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease.
    Ferretti MT; Bruno MA; Ducatenzeiler A; Klein WL; Cuello AC
    Neurobiol Aging; 2012 Jul; 33(7):1329-42. PubMed ID: 21414686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment.
    Prasad KN; Cole WC; Prasad KC
    J Am Coll Nutr; 2002 Dec; 21(6):506-22. PubMed ID: 12480796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.